<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study retrospectively reviewed the medical records of children with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:hpo ids='HP_0000123'>nephritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e>) who were treated at Seoul National University Children's Hospital from 1986 to 2005 (mean duration 8.3+/-4.4 years) </plain></SENT>
<SENT sid="1" pm="."><plain>The records of 77 children (22 male and 55 female) were examined </plain></SENT>
<SENT sid="2" pm="."><plain>The mean age at diagnosis was 11.9+/-3.0 years </plain></SENT>
<SENT sid="3" pm="."><plain>The initial biopsy results revealed a WHO class IV classification for 60 (88.2%) of 68 biopsy proven cases </plain></SENT>
<SENT sid="4" pm="."><plain>Of 77 patients, 67 (87.0%) responded initially to the high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> with or without additional immunosuppressive therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Of the initial responders (67), 30 (44.8%) experienced at least one episode of proteinuric (24) or nephritic (6) flare </plain></SENT>
<SENT sid="6" pm="."><plain>Thirteen patients (16.9%) progressed to either <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> (CRF) or <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>Six (7.8%) patients died </plain></SENT>
<SENT sid="8" pm="."><plain>A Kaplan-Meier estimate of patient survival and CRF-free survival rate was 95.4% and 88.7% at 5 years and 91.8% and 74.7% at 10 years, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis for class IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> revealed male gender (P=0.029), initial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (P=0.001) and absence of remission (P=0.002) to be prognostic factors predicting CRF </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000096'>Glomerulosclerosis</z:hpo> of 10% or more (P=0.005), nephritic flare (P=0.011), and presence of anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibody (P=0.017) or syndrome (P=0.004) were also found to be independent risk factors for CRF </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi> pulse therapy failed to demonstrate superiority over other combined <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> used for the treatment of diffuse proliferative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> </plain></SENT>
</text></document>